Quercetin Targets Multiple Aging Pathways Across Heart, Brain, Bone and Eyes
A sweeping 2025 review maps how the plant compound quercetin combats cardiovascular disease, dementia, osteoporosis, and more at the molecular level.
Summary
Quercetin, a flavonol found in fruits, vegetables, and teas, has emerged as a multi-target compound with broad relevance to aging-related disease. A 2025 review published in Phytotherapy Research synthesizes evidence from PubMed, Scopus, and Web of Science through March 2025, outlining how quercetin's antioxidant, anti-inflammatory, anti-apoptotic, and metabolic regulatory actions converge on shared molecular pathways across cardiovascular, neurological, skeletal, metabolic, and ocular systems. The authors argue for a systems-level view of quercetin's therapeutic potential, covering conditions from heart disease and diabetes to dementia, osteoporosis, and age-related eye disorders. They also highlight bioavailability as a key obstacle and note that personalized delivery systems and biomarker profiling may be needed to unlock its full clinical potential.
Detailed Summary
As the global population ages, interest in natural compounds capable of targeting multiple hallmarks of aging simultaneously has intensified. Quercetin, a widely consumed dietary polyphenol belonging to the flavonol subclass, has become one of the most studied candidates due to its apparent ability to act on several disease-driving mechanisms at once.
This comprehensive 2025 review from Jilin Agricultural Science and Technology College synthesizes literature gathered from PubMed, Scopus, and Web of Science through March 2025. The authors examined in vitro, in vivo, and clinical studies focused on quercetin's role in aging-associated conditions across five major physiological systems: cardiovascular, skeletal, neurological, metabolic, and ocular.
The review identifies four core mechanisms through which quercetin exerts its effects: potent antioxidant activity that neutralizes reactive oxygen species, anti-inflammatory signaling that suppresses chronic low-grade inflammation central to aging, anti-apoptotic actions that protect cells from premature death, and metabolic regulation that influences glucose and lipid homeostasis. These converging mechanisms appear relevant to cardiovascular diseases, osteoporosis, stroke, diabetes, dementia, and age-related eye diseases.
The authors emphasize that quercetin's multi-target profile makes it particularly attractive for a systems-level approach to aging prevention, potentially delaying disease onset and slowing progression across organ systems simultaneously. Advances in delivery technologies and personalized biomarker-guided dosing are highlighted as promising avenues to overcome quercetin's notoriously poor bioavailability.
However, major caveats remain. Most mechanistic evidence derives from preclinical models, clinical data are limited, and optimal dosing and long-term safety in humans are not yet established. The review calls for rigorous clinical trials to translate these promising findings into actionable therapeutic protocols.
Key Findings
- Quercetin modulates antioxidant, anti-inflammatory, anti-apoptotic, and metabolic pathways relevant to multiple aging diseases.
- Protective effects span cardiovascular disease, osteoporosis, stroke, diabetes, dementia, and age-related eye conditions.
- A systems-level framework positions quercetin as a multi-target intervention rather than a single-disease compound.
- Poor bioavailability remains a key barrier; advanced delivery systems and biomarker profiling may optimize efficacy.
- Further clinical trials are needed to define safe, effective dosing regimens for aging populations.
Methodology
This is a comprehensive narrative review, not a meta-analysis or clinical trial. Literature was sourced from PubMed, Scopus, and Web of Science up to March 2025 using keywords related to quercetin, polyphenols, and aging-related diseases. Included studies spanned in vitro, in vivo, and clinical research published in peer-reviewed journals.
Study Limitations
The review relies heavily on preclinical evidence, and human clinical data supporting quercetin's efficacy across these disease domains remain sparse and heterogeneous. Optimal dosing, long-term safety, and patient-specific factors such as genetics and gut microbiome composition are not yet defined. As a narrative review, it is subject to selection bias and does not provide quantitative effect-size estimates.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.